Benzinga··Vandana SinghImmunityBio's ANKTIVA Combo Shows Superior Results Against Rival Bladder Cancer Drugs
ImmunityBio's ANKTIVA combo showed 69.7% response rates versus rivals' 53.4%, with extended durability and 68% fewer adverse events, strengthening its competitive positioning.
JNJIBRXclinical trialbladder cancer